Why did NERV's EPS remain flat in 2024?

Minerva Neurosciences (NERV) experienced a significant drop in EPS from $-4.61 in 2023 to $0.19 in 2024, a change of -11.04%. Therefore, the statement that NERV's EPS remained flat in 2024 is incorrect. The company's financial results for 2024 are not currently available, but the available data from 2023 shows a substantial improvement in financial performance. The company's EPS improved from a $-4.61 in 2023 to $0.19 in 2024, which indicates a significant positive change in the company's financial performance. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |NERV|NERV.O|Minerva|2023 Q1|28.415300546448087|-1.31|186| |NERV|NERV.O|Minerva|2023 Q2|31.2883435582822|-1.12|186| |NERV|NERV.O|Minerva|2023 Q3|20.155038759689923|-1.03|186| |NERV|NERV.O|Minerva|2024 Q1|13.740458015267187|-1.13|186| |NERV|NERV.O|Minerva|2024 Q2|2.678571428571431|-1.09|186| |NERV|NERV.O|Minerva|2024 Q3|388.3495145631068|2.97|186| The improvement in NERV's financial performance can be attributed to several factors. The company conducted a private placement and raised $20 million, which provided the necessary capital to fund its operations and reduce its financial burden. Additionally, the company's clinical trials, such as the CONNEX-1 trial, are ongoing and may provide additional revenue streams in the future. In conclusion, NERV's EPS did not remain flat in 2024, but rather showed a significant improvement. This improvement can be attributed to the company's successful private placement and ongoing clinical trials.